2017 年 52 巻 2-3 号 p. 169-177
Islet transplantation is promising to be capable of relieving glucose instability and improving QOL of type 1 diabetic patients who cannot be controlled of severe hypoglycemic unawareness. In Japan, the phase II clinical trial of islet transplantation for type 1 diabetes patients has been started by using ATG induction and TNF-α inhibition protocol. The primary endpoints for this trial are the proportion of subjects with HbA1c<7.4% and who are free of severe hypoglycemic events one year after the first islet cell infusion. This trial would play an important role in establishing islet transplantation in Japan.
